Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Reteplase

Qureshi Al, Harris-Lane P, Kirmani IF, Janjua N, Divani AA, Mohammad YM, Suarez Jl, Montgomery MO. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke an open-label, dose-ranging, phase I study. Neurosurgery 2006 59 789-796 [discussion 796-787]. [Pg.95]

Alteplase, reteplase, or tenecteplase preferred over strepto kinase in ... [Pg.28]

Pharmacologic management of thrombosis includes local administration of thrombolytic agents. Alteplase (2 mg per port) and reteplase (0.5 unit per port) are the two most commonly used agents today. Urokinase has been used in the past, but after its reintroduction to the United States market, the larger dosed vial size makes it less cost effective than the newer agents. [Pg.397]

Retevase Reteplase Boehringer Man Centocor Treatment of acute myocardial infarction... [Pg.695]

Reteplase 10 unit IV bolus, followed by 10 units IV bolus 30 minutes later ... [Pg.158]

Practice guidelines indicate that a more fibrin-specific agent (alteplase, reteplase, tenecteplase) is preferred over the non-fibrin-specific agent streptokinase. Fibrin-specific agents open a greater percentage of infarct arteries, which results in smaller infarcts and lower mortality. [Pg.63]

Reteplase 10 units IV over 2 minutes, followed 30 minutes later with another 10 units IV over 2 minutes. [Pg.63]

If a fibrinolytic agent is administered, UFH is given concomitantly with alteplase, reteplase, and tenecteplase, but UFH is not administered with streptokinase because no benefit of combined therapy has been demonstrated. Rates of reinfarction are higher if UFH is not given with the fibrin-selective agents. [Pg.65]

Aprotinin (Trasylol) Dextran 40 (Gentran 40, Rheomacrodex) Reteplase (Retavase)... [Pg.50]

Eptifibatide (Integrilin) Reteplase (Retavase) Ticlopidine (Ticlid) Tirofiban (Aggrastat)... [Pg.50]

The laek of glyeosylation as well as the absenee of the EGF and Ki domains (Table 9.11) eonfers an extended serum half-life upon the engineered moleeule. Reteplase-based produets display a serum half-life of up to 20 min, faeilitating its administration as a single bolus injection... [Pg.384]

Ecokinase (Reteplase, rtPA differs from human tPA in that three of its five domains have been deleted. Produced in E. coli) Galenus Mannheim Acute myocardial infarction 1996 (EU)... [Pg.500]

Retavase (Reteplase, rtPA see Ecokinase) Boehringer- Mannheim/ Centocor Acute myocardial infarction 1996 (USA)... [Pg.500]

Plasminogen, an inactive precursor, is activated to plasmin which as a protease is able to break down fibrin clots. The thrombolytic agents in use promote the conversion of plasminogen to plasmin at the site of a thrombus. Indications include post-myocardial infarction treatment. The thrombolytic must be administered within 6 hours for an optimal effect. Other indications are treatment of acute pulmonary thromboembolism, deep-vein thrombosis, acute arterial thrombosis and thromboembolism, as well as in the clearance of arteriovenous catheters and can-nulae. Agents are streptokinase, anistreplase, urokinase, alteplase, reteplase and tenecteplase. [Pg.374]

See other pages where Reteplase is mentioned: [Pg.506]    [Pg.428]    [Pg.429]    [Pg.75]    [Pg.75]    [Pg.79]    [Pg.79]    [Pg.147]    [Pg.28]    [Pg.29]    [Pg.87]    [Pg.92]    [Pg.96]    [Pg.97]    [Pg.105]    [Pg.143]    [Pg.1673]    [Pg.596]    [Pg.616]    [Pg.348]    [Pg.349]    [Pg.597]    [Pg.619]    [Pg.49]    [Pg.43]    [Pg.273]    [Pg.384]    [Pg.374]   
See also in sourсe #XX -- [ Pg.348 ]

See also in sourсe #XX -- [ Pg.146 ]

See also in sourсe #XX -- [ Pg.273 ]

See also in sourсe #XX -- [ Pg.367 ]

See also in sourсe #XX -- [ Pg.264 , Pg.265 ]

See also in sourсe #XX -- [ Pg.273 ]

See also in sourсe #XX -- [ Pg.3 , Pg.56 ]

See also in sourсe #XX -- [ Pg.420 ]

See also in sourсe #XX -- [ Pg.21 ]

See also in sourсe #XX -- [ Pg.577 ]

See also in sourсe #XX -- [ Pg.672 ]

See also in sourсe #XX -- [ Pg.30 , Pg.45 ]

See also in sourсe #XX -- [ Pg.150 ]

See also in sourсe #XX -- [ Pg.485 ]

See also in sourсe #XX -- [ Pg.297 ]

See also in sourсe #XX -- [ Pg.3 , Pg.3 , Pg.166 , Pg.167 ]

See also in sourсe #XX -- [ Pg.960 ]

See also in sourсe #XX -- [ Pg.308 , Pg.309 , Pg.310 ]

See also in sourсe #XX -- [ Pg.273 ]

See also in sourсe #XX -- [ Pg.222 , Pg.270 , Pg.275 ]

See also in sourсe #XX -- [ Pg.141 , Pg.843 , Pg.844 ]

See also in sourсe #XX -- [ Pg.366 ]

See also in sourсe #XX -- [ Pg.50 , Pg.155 , Pg.215 ]

See also in sourсe #XX -- [ Pg.41 ]

See also in sourсe #XX -- [ Pg.394 , Pg.396 , Pg.568 ]



SEARCH



Abciximab Reteplase

Reteplase administration

Reteplase streptokinase, compared

Reteplase, myocardial infarction treatment

Reteplase, recombinant

© 2024 chempedia.info